Targeted.

Novel.

Solutions.

Management Team

​​Matthew Giacalone, Ph.D., MBA -​CEO
Dr. Giacalone has 20 years of experience in the area of minicell biology and the use of minicells as delivery vehicles.  He provides operational oversight as well as corporate, business, and product development expertise to the company.  Dr. Giacalone also manages Vaxiion's robust intellectual property estate and holds over 20 patents and publications in the minicell-based delivery field.  Dr. Giacalone received his Ph.D. from University of California, San Diego and an MBA from San Diego State University through a joint Ph.D./MBA program. 

​

Daniel H. Petree - Chairman​    

Mr.  Petree has over 30 years of experience in the biotechnology industry, serving in a variety of roles including senior operating manager, board of directors member, investment banker and corporate and securities lawyer. Mr. Petree is a co-founder of P2 Partners, LLC (founded in 2000) and Four Oaks Partners (founded in 2012) both of which provided transaction advisory services to small and medium sized life science companies. Both partnerships have ceased operation. Prior to co-founding P2 Partners, Mr. Petree was President and Chief Operating Officer of Axys Pharmaceuticals (NASDAQ: AXYS) a structure based drug design company in South San Francisco. Currently, Mr. Petree serves as a member of the Board of Directors of Sutro Biopharma, Inc. (NASDAQ: STRO) a South San Francisco, CA - based biotechnology company, Ichor Medical Systems, a privately held, San Diego, CA -based biotechnology company and Lipidio Biopharma, a privately held, San Diego, CA -based biotechnology company. Mr. Petree received an A.B. from Stanford University and  a J.D. from the University of Michigan Law School.​​​​